Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen

The objective of this first-in-human study is to assess the safety and effectiveness of the Serranator Sonic Intravascular Lithotripsy (IVL) System™ for the treatment of peripheral artery disease.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Cagent Vascular LLCUpdated: May 8, 2026
Eligibility criteria

Subject is ≥ 18 years of age [+9]

Rutherford Clinical Categories 0, 1, 5 and 6 [+19]

Status: Recruiting

Serranator POINT FORCE Registry

The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Cagent Vascular LLCUpdated: May 7, 2026Locations: 19Duration: 1 Day
Eligibility criteria

Subjects intended to be treated with Serranator® for de-novo or restenotic lesio... [+3]

Subjects with any medical condition that would make him/her an inappropriate can... [+1]

Status: Recruiting

Serrantor OCT Study

TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

Participants needed: 60
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: Cagent Vascular LLCUpdated: May 18, 2025Locations: 2
Eligibility criteria

Rutherford clinical category 4-6 of the target limb [+2]

De novo or restenotic (without prior stent) stenosis (≥70%) or occlusion [+3]